Platform adaptive trial of novel antivirals for early treatment of COVID-19 In the community (PANORAMIC) : protocol for a randomised, controlled, open-label, adaptive platform trial of community novel antiviral treatment of COVID-19 in people at increased risk of more severe disease
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ..
INTRODUCTION: There is an urgent need to determine the safety, effectiveness and cost-effectiveness of novel antiviral treatments for COVID-19 in vaccinated patients in the community at increased risk of morbidity and mortality from COVID-19.
METHODS AND ANALYSIS: PANORAMIC is a UK-wide, open-label, prospective, adaptive, multiarm platform, randomised clinical trial that evaluates antiviral treatments for COVID-19 in the community. A master protocol governs the addition of new antiviral treatments as they become available, and the introduction and cessation of existing interventions via interim analyses. The first two interventions to be evaluated are molnupiravir (Lagevrio) and nirmatrelvir/ritonavir (Paxlovid).
ELIGIBILITY CRITERIA: community-dwelling within 5 days of onset of symptomatic COVID-19 (confirmed by PCR or lateral flow test), and either (1) aged 50 years and over, or (2) aged 18-49 years with qualifying comorbidities. Registration occurs via the trial website and by telephone. Recruitment occurs remotely through the central trial team, or in person through clinical sites. Participants are randomised to receive either usual care or a trial drug plus usual care. Outcomes are collected via a participant-completed daily electronic symptom diary for 28 days post randomisation. Participants and/or their Trial Partner are contacted by the research team after days 7, 14 and 28 if the diary is not completed, or if the participant is unable to access the diary. The primary efficacy endpoint is all-cause, non-elective hospitalisation and/or death within 28 days of randomisation. Multiple prespecified interim analyses allow interventions to be stopped for futility or superiority based on prespecified decision criteria. A prospective economic evaluation is embedded within the trial.
ETHICS AND DISSEMINATION: Ethical approval granted by South Central-Berkshire REC number: 21/SC/0393; IRAS project ID: 1004274. Results will be presented to policymakers and at conferences, and published in peer-reviewed journals.
TRIAL REGISTRATION NUMBER: ISRCTN30448031; EudraCT number: 2021-005748-31.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
BMJ open - 13(2023), 8 vom: 07. Aug., Seite e069176 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gbinigie, Oghenekome [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antiviral Agents |
|---|
| Anmerkungen: |
Date Completed 09.08.2023 Date Revised 20.03.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1136/bmjopen-2022-069176 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360496784 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360496784 | ||
| 003 | DE-627 | ||
| 005 | 20240320233328.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/bmjopen-2022-069176 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1337.xml |
| 035 | |a (DE-627)NLM360496784 | ||
| 035 | |a (NLM)37550022 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gbinigie, Oghenekome |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Platform adaptive trial of novel antivirals for early treatment of COVID-19 In the community (PANORAMIC) |b protocol for a randomised, controlled, open-label, adaptive platform trial of community novel antiviral treatment of COVID-19 in people at increased risk of more severe disease |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.08.2023 | ||
| 500 | |a Date Revised 20.03.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ. | ||
| 520 | |a INTRODUCTION: There is an urgent need to determine the safety, effectiveness and cost-effectiveness of novel antiviral treatments for COVID-19 in vaccinated patients in the community at increased risk of morbidity and mortality from COVID-19 | ||
| 520 | |a METHODS AND ANALYSIS: PANORAMIC is a UK-wide, open-label, prospective, adaptive, multiarm platform, randomised clinical trial that evaluates antiviral treatments for COVID-19 in the community. A master protocol governs the addition of new antiviral treatments as they become available, and the introduction and cessation of existing interventions via interim analyses. The first two interventions to be evaluated are molnupiravir (Lagevrio) and nirmatrelvir/ritonavir (Paxlovid) | ||
| 520 | |a ELIGIBILITY CRITERIA: community-dwelling within 5 days of onset of symptomatic COVID-19 (confirmed by PCR or lateral flow test), and either (1) aged 50 years and over, or (2) aged 18-49 years with qualifying comorbidities. Registration occurs via the trial website and by telephone. Recruitment occurs remotely through the central trial team, or in person through clinical sites. Participants are randomised to receive either usual care or a trial drug plus usual care. Outcomes are collected via a participant-completed daily electronic symptom diary for 28 days post randomisation. Participants and/or their Trial Partner are contacted by the research team after days 7, 14 and 28 if the diary is not completed, or if the participant is unable to access the diary. The primary efficacy endpoint is all-cause, non-elective hospitalisation and/or death within 28 days of randomisation. Multiple prespecified interim analyses allow interventions to be stopped for futility or superiority based on prespecified decision criteria. A prospective economic evaluation is embedded within the trial | ||
| 520 | |a ETHICS AND DISSEMINATION: Ethical approval granted by South Central-Berkshire REC number: 21/SC/0393; IRAS project ID: 1004274. Results will be presented to policymakers and at conferences, and published in peer-reviewed journals | ||
| 520 | |a TRIAL REGISTRATION NUMBER: ISRCTN30448031; EudraCT number: 2021-005748-31 | ||
| 650 | 4 | |a Clinical Trial Protocol | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a clinical trials | |
| 650 | 4 | |a primary care | |
| 650 | 4 | |a therapeutics | |
| 650 | 4 | |a virology | |
| 650 | 7 | |a nirmatrelvir and ritonavir drug combination |2 NLM | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 700 | 1 | |a Ogburn, Emma |e verfasserin |4 aut | |
| 700 | 1 | |a Allen, Julie |e verfasserin |4 aut | |
| 700 | 1 | |a Dorward, Jienchi |e verfasserin |4 aut | |
| 700 | 1 | |a Dobson, Melissa |e verfasserin |4 aut | |
| 700 | 1 | |a Madden, Tracie-Ann |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Ly-Mee |e verfasserin |4 aut | |
| 700 | 1 | |a Lowe, David M |e verfasserin |4 aut | |
| 700 | 1 | |a Rahman, Najib |e verfasserin |4 aut | |
| 700 | 1 | |a Petrou, Stavros |e verfasserin |4 aut | |
| 700 | 1 | |a Richards, Duncan |e verfasserin |4 aut | |
| 700 | 1 | |a Hood, Kerenza |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Mahendra |e verfasserin |4 aut | |
| 700 | 1 | |a Saville, Benjamin R |e verfasserin |4 aut | |
| 700 | 1 | |a Marion, Joe |e verfasserin |4 aut | |
| 700 | 1 | |a Holmes, Jane |e verfasserin |4 aut | |
| 700 | 1 | |a Png, May Ee |e verfasserin |4 aut | |
| 700 | 1 | |a Hayward, Gail |e verfasserin |4 aut | |
| 700 | 1 | |a Lown, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Harris, Victoria |e verfasserin |4 aut | |
| 700 | 1 | |a Jani, Bhautesh |e verfasserin |4 aut | |
| 700 | 1 | |a Hart, Nigel |e verfasserin |4 aut | |
| 700 | 1 | |a Khoo, Saye |e verfasserin |4 aut | |
| 700 | 1 | |a Rutter, Heather |e verfasserin |4 aut | |
| 700 | 1 | |a Chalk, Jem |e verfasserin |4 aut | |
| 700 | 1 | |a Standing, Joseph F |e verfasserin |4 aut | |
| 700 | 1 | |a Breuer, Judith |e verfasserin |4 aut | |
| 700 | 1 | |a Lavallee, Layla |e verfasserin |4 aut | |
| 700 | 1 | |a Hadley, Elizabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Cureton, Lucy |e verfasserin |4 aut | |
| 700 | 1 | |a Benysek, Magdalena |e verfasserin |4 aut | |
| 700 | 1 | |a Andersson, Monique I |e verfasserin |4 aut | |
| 700 | 1 | |a Francis, Nick |e verfasserin |4 aut | |
| 700 | 1 | |a Thomas, Nicholas P B |e verfasserin |4 aut | |
| 700 | 1 | |a Evans, Philip |e verfasserin |4 aut | |
| 700 | 1 | |a van Hecke, Oliver |e verfasserin |4 aut | |
| 700 | 1 | |a Koshkouei, Mona |e verfasserin |4 aut | |
| 700 | 1 | |a Coates, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Barrett, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Bateman, Clare |e verfasserin |4 aut | |
| 700 | 1 | |a Davies, Jennifer |e verfasserin |4 aut | |
| 700 | 1 | |a Raymundo-Wood, Ivy |e verfasserin |4 aut | |
| 700 | 1 | |a Ustianowski, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Nguyen-Van-Tam, Jonathan |e verfasserin |4 aut | |
| 700 | 1 | |a Carson-Stevens, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Hobbs, Richard |e verfasserin |4 aut | |
| 700 | 1 | |a Little, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Butler, Christopher C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMJ open |d 2011 |g 13(2023), 8 vom: 07. Aug., Seite e069176 |w (DE-627)NLM215724372 |x 2044-6055 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2023 |g number:8 |g day:07 |g month:08 |g pages:e069176 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/bmjopen-2022-069176 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2023 |e 8 |b 07 |c 08 |h e069176 | ||